Whitehawk Therapeutics (WHWK) Fireside Chat summary

Introduction and agenda

• The discussion featured the President and CSO of a therapeutics company, focusing on their ADC pipeline, platform technology, and strategic direction.

Background and experience of the speaker

• The company underwent a transformation from a commercial-stage entity to a development-focused ADC company, leveraging proceeds from an asset sale and PIPE financing.

• The leadership team includes individuals with deep ADC experience and multiple IND and clinical filings.

Current industry trends

• ADCs are gaining traction as targeted cancer therapies, with multiple modalities (CAR T, bispecifics, monoclonals) competing for similar targets.

• There is increasing focus on optimizing therapeutic index and minimizing off-target toxicity in next-generation ADCs.

• Biomarker-driven patient selection and expression profiling are becoming standard in oncology drug development.